Keros Therapeutics (NASDAQ:KROS) Downgraded by BTIG Research to “Neutral”

BTIG Research lowered shares of Keros Therapeutics (NASDAQ:KROS) from a buy rating to a neutral rating in a research report report published on Thursday morning, Marketbeat.com reports.

A number of other equities research analysts also recently weighed in on the company. William Blair downgraded Keros Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Thursday. Scotiabank initiated coverage on Keros Therapeutics in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $77.00 target price for the company. Guggenheim reaffirmed a “buy” rating and set a $102.00 target price (up previously from $96.00) on shares of Keros Therapeutics in a research report on Wednesday, December 4th. Cantor Fitzgerald reissued an “overweight” rating on shares of Keros Therapeutics in a research report on Friday, November 22nd. Finally, Wedbush reaffirmed an “outperform” rating and set a $84.00 price objective on shares of Keros Therapeutics in a report on Thursday, November 7th. Three research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $95.22.

Keros Therapeutics Stock Performance

KROS stock opened at $18.43 on Thursday. The firm has a 50 day simple moving average of $59.95 and a 200 day simple moving average of $52.83. Keros Therapeutics has a 52 week low of $15.67 and a 52 week high of $73.00.

Keros Therapeutics (NASDAQ:KROS) last issued its earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The company had revenue of $0.39 million for the quarter. During the same period in the prior year, the business earned ($1.33) earnings per share. The firm’s revenue for the quarter was up 4750.0% on a year-over-year basis. On average, sell-side analysts forecast that Keros Therapeutics will post -5.26 earnings per share for the current year.

Institutional Investors Weigh In On Keros Therapeutics

A number of institutional investors have recently bought and sold shares of the business. FMR LLC raised its stake in shares of Keros Therapeutics by 3.8% in the 3rd quarter. FMR LLC now owns 4,899,134 shares of the company’s stock valued at $284,493,000 after buying an additional 179,374 shares in the last quarter. Alkeon Capital Management LLC raised its position in Keros Therapeutics by 18.7% in the third quarter. Alkeon Capital Management LLC now owns 1,897,601 shares of the company’s stock worth $110,194,000 after purchasing an additional 298,694 shares in the last quarter. Darwin Global Management Ltd. lifted its stake in Keros Therapeutics by 6.3% during the second quarter. Darwin Global Management Ltd. now owns 1,525,902 shares of the company’s stock worth $68,772,000 after purchasing an additional 89,952 shares during the period. Point72 Asset Management L.P. boosted its holdings in Keros Therapeutics by 155.9% during the third quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company’s stock valued at $55,025,000 after purchasing an additional 577,220 shares in the last quarter. Finally, Holocene Advisors LP grew its stake in shares of Keros Therapeutics by 22.5% in the 3rd quarter. Holocene Advisors LP now owns 843,110 shares of the company’s stock valued at $48,959,000 after purchasing an additional 154,784 shares during the period. Institutional investors and hedge funds own 71.56% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.